Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Pfizer Inc. : Pfizer Names Olivier Brandicourt as President and General Manager, Emerging Markets and Established Products Business Units

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/23/2012 | 01:35pm CET

John Young Named President and General Manager, Primary Care Business Unit

Pfizer Inc. (NYSE: PFE) named Olivier Brandicourt as President and General Manager of the Emerging Markets and Established Products Business Units, effective June 1, 2012. He will succeed David Simmons, who is leaving Pfizer to become the Chairman and CEO of Pharmaceutical Product Development Inc. (PPD), a privately held global contract research organization.

"Olivier is ideally suited to take on this new role," said Ian Read, Pfizer Chairman and CEO. "He has more than 20 years of global experience in the pharmaceutical industry. Olivier is both a physician and proven business leader who understands the many challenges of today's changing industry and healthcare landscape."

Dr. Brandicourt has held senior positions at Pfizer across a range of disciplines, including medical and marketing, as well as country and regional management roles in Latin America, Europe, Canada, the United Kingdom and the United States. Most recently, he served as President and General Manager of the Primary Care Business Unit and is a member of the Pfizer Executive Leadership Team. He is an Honorary Fellow of the Royal College of Physicians in London and a trustee of the Children's Aid Society of New York.

John Young, currently Regional President of Europe and Canada for the Primary Care business, is appointed President and General Manager of the Primary Care Business Unit and will join the Company's Executive Leadership Team, effective June 1, 2012. Over his 25-year career with Pfizer, Mr. Young has held a number of commercial positions with the company, including country and regional management roles in Australia/New Zealand and the United Kingdom.

"John has a deep understanding of the primary care landscape and will be a strong leader for this significant part of our business. We are indeed fortunate to have such a deep bench of talented leaders who can quickly assume new roles and maintain our momentum," Read added.

"We thank David for his contributions throughout his 15-year career at Pfizer. Under his leadership, the Established Products Business Unit was created, expanding Pfizer's market reach while also helping to ensure patients have the access to high-quality, affordable medicines they need."

Pfizer Inc: Working Together for a Healthier World™

At Pfizer (NYSE: PFE), we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Pfizer Inc.
Media Contact:
Joan Campion, 212-733-2798
or
Investors Contact:
Chuck Triano, 212-733-3901


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
02/24 PFIZER : Prices $1,065,000,000 Debt Offering
02/24 PFIZER INC. (LON : PFZ) Files An 8-K Departure of Directors or Certain Officers;..
02/23DJPFIZER : Files 8K - Changes Executive Management
02/23 PFIZER INC : Financial Statements and Exhibits (form 8-K)
02/23 PFIZER : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
02/23 PFIZER : Ronald E. Blaylock Elected to Pfizer’s Board of Directors
02/23 Spark Therapeutics Reports 2016 Financial Results and Business Highlights
02/23 PFIZER : AIDS ACTION COMMITTEE $200K grant to support Needle Exchange
02/22 MANUFACTURING DELAY OF GENERIC DRUG : PFE) A Relief For Teva Pharmaceutical Ind..
02/22 PFIZER : Viagra maker Pfizer cites poor performance for stock de-listing
More news
Sector news : Pharmaceuticals - NEC
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Advertisement
Financials ($)
Sales 2017 53 326 M
EBIT 2017 20 087 M
Net income 2017 12 686 M
Debt 2017 28 566 M
Yield 2017 3,72%
P/E ratio 2017 15,40
P/E ratio 2018 13,92
EV / Sales 2017 4,43x
EV / Sales 2018 4,16x
Capitalization 207 902 M
More Financials
Chart PFIZER INC
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 38,0 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Ole Isacson Chief Scientific Officer
W. Don Cornwell Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC13.96%207 902
JOHNSON & JOHNSON5.63%333 891
ROCHE HOLDING LTD.5.98%210 192
PFIZER INC.4.86%207 902
NOVARTIS AG4.72%202 648
MERCK & CO., INC.11.86%182 412
More Results